Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimenMeghan C. Thompson, Anthony R. Mato, Martin Šimkovič et al.|Blood Advances|2022Cited by 57
Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor geneMarcus Lefebure, Ricky W. Johnstone|Nature Communications|2017Cited by 54
CLL-769: Efficacy and Safety of Zanubrutinib in a Fit Subgroup of Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL): Post Hoc Analyses From the SEQUOIA StudyMazyar Shadman, Talha Munir, Danielle M. Brander et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 1
An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLLMazyar Shadman, Talha Munir, Constantine S. Tam et al.|Blood Advances|2026Cited by 1